Welcome to our dedicated page for INOVIO PHARMACEUTICALS SEC filings (Ticker: INO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INOVIO PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INOVIO PHARMACEUTICALS's regulatory disclosures and financial reporting.
INOVIO PHARMACEUTICALS, INC. Chief Medical Officer Michael John Sumner reported several equity compensation transactions on May 20, 2026. He exercised 9,450 restricted stock units, receiving common shares, and 2,693 shares were withheld by the company to cover related tax obligations.
Sumner also received a new grant of 37,684 restricted stock units, which vest in three annual installments from February 26, 2027 through February 26, 2029. In addition, he was granted 46,876 stock options with a $1.73 exercise price, vesting over the same three-year period under INOVIO’s amended 2023 Omnibus Incentive Plan, which shareholders approved on May 20, 2026.
INOVIO PHARMACEUTICALS, INC. CFO Peter Kies reported several equity compensation events on common stock and related awards. On May 20, 2026, 8,700 restricted stock units vested and were settled into common shares, with 4,688 shares withheld at a price of $1.23 to cover tax obligations. Following these transactions, he held 42,854 common shares directly and 375 common shares indirectly through his spouse. Kies also received new grants of 32,480 restricted stock units and 39,760 stock options with a $1.73 exercise price expiring on May 20, 2036, approved under Inovio’s amended and restated 2023 Omnibus Incentive Plan after shareholder approval.
INOVIO PHARMACEUTICALS, INC. reported routine equity compensation and related tax withholding transactions for CEO Jacqueline Elizabeth Shea. On May 20, 2026, 28,296 restricted stock units vested and were settled into common shares, with 12,306 shares withheld at $1.23 per share to cover tax obligations. Shea exercised a derivative award for 28,296 shares of common stock and, following this exercise, held 123,327 common shares directly, while after the tax withholding entry she held 111,021 shares directly. She also received new grants of 100,240 restricted stock units and 123,760 stock options with a $1.73 exercise price, vesting in equal annual installments from February 26, 2027 through February 26, 2029.
Inovio Pharmaceuticals, Inc. reported governance changes and voting results from its 2026 annual stockholder meeting. On May 19, 2026, the board approved a bylaws amendment clarifying that the Chairman of the Board is not an officer unless specifically designated, formally creating a Lead Independent Director role when the Chief Executive Officer also serves as Chairman, and updating the order of presiding officers at board and stockholder meetings.
On May 20, 2026, stockholders holding 40,670,629 shares, or 58.57% of the 69,438,100 shares entitled to vote, were present or represented by proxy. All eight director nominees were elected. Stockholders ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026, approved on a non-binding basis the compensation of named executive officers, and approved amendments to the Amended and Restated 2023 Omnibus Incentive Plan.
INOVIO PHARMACEUTICALS, INC. Chief Executive Officer Jacqueline Elizabeth Shea reported routine equity compensation activity involving restricted stock units. On May 15, 2026, 17,744 restricted stock units were exercised into common shares as part of a 53,233-unit award that vested in three annual tranches.
In connection with this vesting and settlement, the issuer withheld 7,717 shares of common stock at $1.30 per share to satisfy Shea’s tax withholding obligations, rather than selling shares in the open market. Following these transactions, Shea directly held 95,031 shares of INOVIO common stock.
INOVIO PHARMACEUTICALS, INC. CFO Peter Kies reported routine equity compensation activity involving restricted stock units. On May 15, 2026, 4,771 restricted stock units were exercised and converted into an equal number of common shares, consistent with a vesting schedule covering 14,313 units.
In a related transaction that day, 2,571 common shares were withheld by the issuer at $1.30 per share to satisfy Kies’s tax withholding obligations tied to this vesting and settlement. These tax-withholding shares were not an open-market sale.
Following these transactions, Kies directly holds 38,842 common shares, and his spouse indirectly holds an additional 375 common shares reported as indirect ownership.
INOVIO PHARMACEUTICALS, INC. Chief Scientific Officer Laurent Humeau reported routine equity compensation activity involving restricted stock units. On May 15, 2026, 4,771 restricted stock units converted into common stock, and 1,712 shares were withheld by the company to cover tax obligations. Following these transactions, Humeau directly holds 42,959 shares of common stock.
INOVIO PHARMACEUTICALS Chief Medical Officer Michael John Sumner exercised 2,385 restricted stock units into 2,385 shares of common stock on May 15, 2026. To cover related tax obligations, 680 shares were withheld by the company at $1.30 per share. After these transactions, he directly holds 35,281 shares of INOVIO common stock.
Inovio Pharmaceuticals, Inc. ownership disclosure: Highbridge Capital Management LLC reports beneficial ownership of 6,190,475 shares of Common Stock issuable upon exercise of warrants, representing 8.2% of the class. The percentage is calculated using 69,091,956 shares outstanding as of March 12, 2026 and assumes the exercise of the warrants held by the Highbridge Funds.
INOVIO Pharmaceuticals reported a first-quarter 2026 net loss of $19.7 million, or $0.28 per share, roughly in line with the prior year. Operating expenses fell to $21.9 million from $25.1 million as both R&D and G&A spending decreased.
The company ended March 31, 2026 with $37.7 million in cash, cash equivalents and short-term investments, before adding $16.0 million of net equity offering proceeds in April. Management expects this liquidity to fund operations into the first quarter of 2027, beyond the FDA’s target October 30, 2026 PDUFA date for lead candidate INO-3107.
The Biologics License Application for INO-3107 in recurrent respiratory papillomatosis is under active FDA review in the accelerated approval program, following completion of the mid-cycle review. INOVIO is preparing for a potential 2026 U.S. commercial launch and pursuing partnerships on other pipeline assets, including a GBM collaboration with Akeso for INO-5412.